论文部分内容阅读
目的探讨甘氨双唑钠对食管癌放射治疗增敏作用的临床疗效和安全性。方法计算机检索eCochrane Library、PubMed、EMbase、CBM、CNKI、VIP和WanFang Data中甘氨双唑钠对食管癌放射治疗增敏作用的随机对照试验(RCT),检索时限均从建库至2012年2月1日。并通过手检和机检Google Scholar、MedicalMartix等搜索引擎查找相关参考文献及灰色文献,联系本领域专家、相关文献通讯作者等以获取以上检索未发现的信息。根据纳入排除标准筛选文献,对符合条件的RCT由2位研究者独立进行资料提取和质量评价后,采用RevMan 5.1软件进行Meta分析。结果纳入17个RCT,共1 475例患者。Meta分析结果显示:①在治疗食管癌的近期疗效方面,甘氨双唑钠联合放疗优于单纯放疗,其差异有统计学意义[OR=3.51,95%CI(2.44,5.07),P<0.000 01]。②在提高食管癌患者1和2年生存率方面,甘氨双唑钠联合放疗优于单纯放疗,其差异有统计学意义[1年生存率:OR=2.90,95%CI(1.91,4.39),P<0.000 01;2年生存率:OR=1.95,95%CI(1.21,3.15),P=0.006];在提高3年生存率方面,两组差异也有统计学意义[OR=2.28,95%CI(1.16,4.49),P=0.02]。③甘氨双唑钠联合放疗不增加骨髓抑制、黏膜反应、放射性食管炎、放射性肺炎等毒副反应。结论甘氨双唑钠联合放疗治疗食管癌,近期疗效优于单纯放疗,且能提高1、2、3年生存率,但在生存质量和毒副反应方面,由于纳入研究数量和质量有限,需进一步证实。
Objective To investigate the clinical efficacy and safety of glycidodiazole sodium in radiosensitization of esophageal cancer. Methods Randomized controlled trials (RCTs) of glycotriazole sodium in radiosensitization of esophageal cancer in eCochrane Library, PubMed, EMbase, CBM, CNKI, VIP and WanFang Data were searched by computer. On the 1st. And through the manual inspection and machine inspection Google Scholar, MedicalMartix and other search engines to find the relevant references and gray literature, contact with experts in the field, relevant literature and other authors to retrieve the above search did not find the information. Based on the screening criteria included in the exclusion criteria, the qualified RCTs were independently subjected to data extraction and quality evaluation by two investigators, and Meta-analysis was performed using RevMan 5.1 software. Results 17 RCTs were enrolled in a total of 1,475 patients. Meta analysis showed that: (1) In the short-term curative effect of esophageal cancer, the combination of glycididazole and radiotherapy is better than radiotherapy alone (OR = 3.51,95% CI 2.44,5.07, P <0.000 01]. ② In improving the 1-year and 2-year survival rates of patients with esophageal cancer, glycopyrrolate combined with radiotherapy is superior to radiotherapy alone, the difference was statistically significant [1-year survival rate: OR = 2.90,95% CI (1.91,4.39) , P <0.000 01; 2-year survival rate: OR = 1.95, 95% CI (1.21, 3.15, P = 0.006); There was also a significant difference between the two groups in improving 3-year survival [OR = 2.28,95 % CI (1.16, 4.49), P = 0.02]. ③ glycopyrrolate sodium combined with radiotherapy does not increase bone marrow suppression, mucosal reactions, radiation esophagitis, radiation pneumonitis and other toxic reactions. Conclusions Glynidiazole combined with radiotherapy in the treatment of esophageal cancer is superior to radiotherapy alone in the short term and can improve the 1, 2 and 3 year survival rates. However, due to the limited number and quality of studies included in the quality of life and adverse reactions, Further confirmed.